Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.55 (market cap $115.19B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 23.6× Travere Therapeutics Inc. Common Stock's market cap, and iShares 0 3 Month Treasury Bond ETF is more actively traded (18,240,700 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 51 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SGOV | TVTX | |
|---|---|---|
Market Cap | $115.19B | $4.88B |
Volume | 18,240,700 | 1,668,577 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $67.52 |
52-Week Low | $100.28 | $26.79 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52 with no price change. The technical outlook is bearish, driven by moving averages, while oscillators are neutral. Recent corporate actions include scheduled dividend payments through late 2026. Market sentiment is influenced by a significant bond selloff and rising Treasury yields, with institutional activity showing a reduction in holdings by Envestnet Asset Management.
The outlook for SGOV is cautious amid a challenging bond market environment. Investment opportunities lie in its short-duration Treasury exposure during rate volatility, but risks include prolonged high interest rates and inflation pressures. Investors should weigh the ETF's stability against macroeconomic headwinds impacting fixed income.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
